EMVision Medical Devices (ASX:EMV) started a validation trial for its first commercial device, the emu bedside brain scanner, to support a De Novo clearance from the US Food and Drug Administration, a filing on the Australian bourse on Thursday showed.
The company secured an Australian ethics approval, and The Royal Melbourne Hospital was greenlit as the first Australian hospital after a successful site initiation visit. Operator training is in progress.
An emu device was shipped to the first US site, the University of Texas Health Science Center at Houston Medical School and Memorial Hermann-Texas Medical Center. A site initiation visit is planned for the coming weeks.
Further trial sites in the US and Australia will be named and activated shortly, per the filing.
The scanner is a non-invasive, non-ionizing device that uses ultra-high frequency radiofrequency scanning technology combined with advanced artificial intelligence-based algorithms to assist in point-of-care stroke diagnosis.
The company's shares gained over 5% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。